Orchestra BioMed receives $20 million from Medtronic under financing pact
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
May 6, 2026 8:00 AM EDTPayment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (BACKBEAT Trial) evaluating Atrioventricular Interval Modulation Therapy (AVIM Therapy) in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and MedtronicThis payment, together with $15 million received from Ligand and announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements
NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq:... More
